Multi-omics integration identifies ASPH and PTTG1 as potential causal drivers of lung adenocarcinoma progression and immune evasion
Integrating single-cell sequencing, MR-based causality, clinical validation, and functional experiments, we identified ASPH and PTTG1 as key regulators of LUAD angiogenesis and immune evasion. These findings substantiate ASPH/PTTG1 as promising biomarkers and therapeutic targets, offering new insights into precision therapies integrating anti-angiogenic and immunomodulatory strategies.
Authors
- Meifeng Chen (ORCID: https://orcid.org/0000-0002-7170-0843)
- Deyun Cheng
- Na Huang (ORCID: https://orcid.org/0000-0001-5799-1894)
- Kai Yang (ORCID: https://orcid.org/0000-0002-0443-4493)
- Wengui Duan (ORCID: https://orcid.org/0000-0001-8140-0011)
- Yao Wu (ORCID: https://orcid.org/0000-0001-8579-8266)
- Xia Zhao (ORCID: https://orcid.org/0000-0002-2379-9447)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1689275
- Primary Topic
- Angiogenesis and VEGF in Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00